Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma |
| |
| Affiliation: | 1. Postgraduate School of Diagnostic and Interventional Radiology, University of Milan - Università degli Studi di Milano, Via Rodolfo Morandi 30, 20097 San Donato Milanese (MI), Italy;2. Unità Operativa di Endoscopia, Azienda Ospedaliera Santi Paolo e Carlo, Presidio San Paolo, Via di Rudinì 8, 20142 Milan, Italy;3. Unità Operativa di Chirurgia II, Azienda Ospedaliera Santi Paolo e Carlo, Presidio San Paolo, Via di Rudinì 8, 20142 Milan, Italy;4. Unità Operativa di Radiologia, ASST Fatebenefratelli Sacco, Via GB Grassi 74, 20157 Milan, Italy;1. Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate 1200 Woluwe Saint Lambert, Brussels, Belgium;2. Department of Surgery and Abdominal Organ Transplantation, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate 1200 Woluwe Saint Lambert, Brussels, Belgium;3. Department of Pathology, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate 1200 Woluwe Saint Lambert, Brussels, Belgium;4. Department of Hepatology, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate 1200 Woluwe Saint Lambert, Brussels, Belgium;1. Gastroenterology, Hepatology and Nutrition, The Ohio State Wexner Medical Center, Columbus Ohio, United States of America 43210;2. Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio, United States of America 43210;1. Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Université de Picardie Jules Verne, France;2. Gastroenterology Unit, Compiègne Hospital, France;3. Gastroenterology Unit, Polyclinique Saint Claude, Saint Quentin, France;4. Biostatistics Department, Amiens University Hospital, France;1. Service d''Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d''Angers, Angers, France;2. Laboratoire HIFIH, UPRES EA3859, SFR 4208, Université d''Angers, Angers, France;3. Université de Nantes, CHU Nantes, CNRS, INSERM, l''Institut du Thorax, Nantes, France;4. Département de Médecine Générale, Université Côte d''Azur, Nice, France;5. Département de Médecine Générale, Université d''Angers, Angers, France;6. Département d''Endocrinologie, Diabétologie et Nutrition, Hôpital Brabois et Université de Lorraine, Vandoeuvre Lès Nancy, France |
| |
| Abstract: | ObjectiveTo investigate the efficacy of camrelizumab plus transarterial chemoembolization (TACE) on massive hepatocellular carcinoma (HCC) patients.MethodsA total of 92 cases with massive HCC from October 2019 to January 2021 were prospectively enrolled and randomly divided into the study group (n = 46) and the control group (n = 46). The control group received TACE while the study group were treated with camrelizumab plus TACE. The primary end points were clinical efficacy and adverse events. And the secondary end points were liver function, and alpha fetoprotein (AFP), carcino-embryonic antigen (CEA), carbohydrate antigen 19–9 (CA19–9) levels before and after treatment.ResultsAll participants were followed-up for 7 to 24 months, with a median of 12 months. Patients in the study group received TACE for 1–3 times, with an average of (2.01 ± 0.09) times, while patients in the control group receive TACE for 2–4 times, with an average of (3.78 ± 0.12) times, and the control group received significantly more TACEs (χ2 = 5.518, P = 0.019). During the follow-up, the response rate and disease control rate of the study group were significantly higher than those of the control group (χ2 = 5.518, P = 0.019; χ2 = 4.467, P = 0.041). Before treatment, the levels of total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alpha-fetoprotein (AFP), CEA, and CA19–9 were comparable between the groups (P > 0.05). After treatment, the levels of TBIL, ALT, AST, AFP, CEA, and CA19–9 decreased, and the above indicators in the study group were significantly lower than those in the control group (P < 0.05). All patients showed transient liver damage, vomiting, nausea, fever and abdominal pain after surgery, and their symptoms were relieved after symptomatic treatment. Adverse events occurred in 9 cases in the study group, and 3 cases in the control group (χ2 = 3.419, P = 0.064).ConclusionCompared with TACE alone, camrelizumab plus TACE treatment can significantly improve the liver function of patients with massive HCC and enhance the treatment effect, which is worthy of clinical promotion. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
